St. Jude to begin Angstrom ICD implants in Europe this fall, firm says at Piper Jaffray conference.
This article was originally published in The Gray Sheet
ST. JUDE TO BEGIN IMPLANTING ANGSTROM SERIES OF ICDs IN EUROPE by the end of September, Terry Shepherd, acting chief financial officer, said June 18 at the Piper Jaffray investment conference in Minneapolis. The new line of 44 cc single-chamber implantable cardioverter defibrillators, which were developed by the firm's Ventritex unit, includes the Angstrom II, as well as a more advanced version called the Angstrom MD, Shepherd said. St. Jude plans simultaneous premarket approval application supplement submissions to FDA, the company says.
You may also be interested in...
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.